30 September 2009, Fordham, Cambridgeshire, UK: A commercial pioneer of biomarkers in drug development, Quotient Bioresearch offers valuable know-how in marker development, the establishment and validation of methods, and routine quantification of close to 250 different biomarkers.(2005 - 2009), and stories appear daily about the discovery of potential biomarkers, Quotient continues to lead the way by investing in new technology and the early adoption of new analytical platforms.
Dr David Griffiths, business development director at Quotient commented: Biomarkers of disease have long played an important role in diagnostic medicine and are now established as a key part of most drug development programmes. Quotient has developed world-leading expertise in mass spectrometry and immunochemistry-based techniques including its pioneering BioMSâ„¢ approach and latest technologies including Gyrolabâ„¢, and MSDâ„¢ electrochemiluminescence. .
Dr Steve Pleasance, managing director of bioanalytical sciences, added: We have a track record of adopting and adapting new technologies before our clients do - as a result, the Quotient team can often verify their benefits and advise companies on the most appropriate platforms to address their development needs..
Biomarkers can be correlated with biological events to validate drug targets or to predict drug response. In addition, they may be used to characterize and stratify patient populations, helping researchers understand the extent to which a new drug reaches its intended therapeutic target. Importantly, data from clinically validated biomarkers is becoming increasingly required by regulators as they make decisions regarding drug approval.